Hikma Pharmaceuticals (HIK) Stock Rating Lowered by Jefferies Group
Hikma Pharmaceuticals (LON:HIK) was downgraded by analysts at Jefferies Group to an “underperform” rating in a research note issued on Wednesday. They currently have a GBX 895 ($12.14) price target on the stock, down from their previous price target of GBX 1,074 ($14.56). Jefferies Group’s target price points to a potential downside of 11.69% from the company’s previous close.
HIK has been the topic of several other reports. Stifel Nicolaus decreased their price target on shares of Hikma Pharmaceuticals from GBX 1,320 ($17.90) to GBX 1,000 ($13.56) and set a “hold” rating on the stock in a research note on Thursday, November 9th. Numis Securities upgraded shares of Hikma Pharmaceuticals to a “buy” rating and set a GBX 1,300 ($17.63) price objective on the stock in a report on Thursday, November 9th. Peel Hunt reiterated a “hold” rating and set a GBX 1,390 ($18.85) price objective on shares of Hikma Pharmaceuticals in a report on Tuesday, October 31st. JPMorgan Chase & Co. cut their price objective on shares of Hikma Pharmaceuticals from GBX 1,500 ($20.34) to GBX 1,250 ($16.95) and set a “neutral” rating on the stock in a report on Friday, October 6th. Finally, Morgan Stanley reiterated an “equal weight” rating and set a GBX 1,100 ($14.92) price objective on shares of Hikma Pharmaceuticals in a report on Friday, December 1st. Two analysts have rated the stock with a sell rating, six have assigned a hold rating and two have issued a buy rating to the company’s stock. Hikma Pharmaceuticals currently has a consensus rating of “Hold” and a consensus target price of GBX 1,171 ($15.88).
Hikma Pharmaceuticals (LON:HIK) traded down GBX 4 ($0.05) during trading on Wednesday, hitting GBX 1,013.50 ($13.74). 427,162 shares of the company’s stock traded hands, compared to its average volume of 720,152. Hikma Pharmaceuticals has a one year low of GBX 906.50 ($12.29) and a one year high of GBX 2,346 ($31.81). The firm has a market cap of $2,410.00 and a PE ratio of 2,027.00.
Hikma Pharmaceuticals Company Profile
Hikma Pharmaceuticals Plc is a pharmaceutical company. The Company is focused on developing, manufacturing and marketing a range of both branded and non-branded generic and in-licensed products. The Company’s segments include Branded, Injectables, Generics and Others. It sells branded generics and in-licensed patented products across the Middle East and North Africa (MENA) region and other markets.
Receive News & Ratings for Hikma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.